Wegovy
Novo Nordisk’s High-Dose Wegovy Demonstrates Superior Weight Loss of 20.7% in Phase IIIb Trial
Novo Nordisk, Wegovy, semaglutide, obesity treatment, weight loss, Phase IIIb trial, STEP UP trial
Medicare Selects Ozempic, Wegovy for Price Negotiations: A Step Towards Lowering Prescription Drug Costs
Medicare, drug price negotiations, Ozempic, Wegovy, Inflation Reduction Act, prescription drug costs, seniors, healthcare.
Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy
Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk
Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study
Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5
Novo Nordisk’s Wegovy Shows Superior Improvement in Liver Fibrosis and MASH Resolution in Phase III ESSENCE Trial
Novo Nordisk, Wegovy, semaglutide, MASH, liver fibrosis, Phase III ESSENCE trial, Madrigal Pharmaceuticals, Rezdiffra
FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy
FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment
Novo Nordisk and Viatris Settle Patent Dispute Over Ozempic and Wegovy, Keeping Generic Entry Date Undisclosed
Novo Nordisk, Viatris, Mylan Pharmaceuticals, Ozempic, Wegovy, Patent Dispute, Generic Entry Date, Settlement Agreement
Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing
Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.
Novo Nordisk CEO Faces Senate Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Senate Hearing, Ozempic, Wegovy, Drug Prices, Pharmacy Benefit Managers (PBMs), Insurance Coverage, Healthcare System
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market